The influence of chitosan and sodium alginate and formulation variables on the formation and drug release from pellets prepared by extrusion/spheronisation

被引:39
作者
Chatchawalsaisin, J
Podczeck, F
Newton, JM
机构
[1] Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England
[2] Univ Sunderland, Sunderland Sch Pharm, Sunderland SR1 3SD, England
关键词
drug release; extrusion/spheronisation; hydrophilic polymers (chitosan sodium alginate); pellet properties;
D O I
10.1016/j.ijpharm.2004.01.025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The influence of the incorporation of two oppositely charged hydrophilic natural polymers, chitosan and sodium alginate, alone and in combination, on the ability of formulations containing a model drug (paracetamol) to form spherical pellets by the process of extrusion/spheronisation and the properties of the pellets, has been undertaken. A statistically experimental design was employed to allow the major factors which determined the properties of the pellets, to be identified. A standardised procedure was used to prepare the pellets with a ram producing the extrudate for spheronisation. Statistical analysis of the results indicated that the formulation variables of the type and level of the polymer, the proportion of the model drug, and the proportion of the microcrystalline cellulose influenced (a) the quantity of liquid binder required to produce a good formulation (narrow size range and high value for the shape factor indicating sphericity), (b) the steady-state extrusion force, (c) the pellet perimeter, (d) the apparent pellet density and (e) the porosity of the pellets. The median size of the pellets of the "good formulation" could only be related to the chitosan and sodium alginate content of the formulations. The proportion of the drug, chitosan and sodium alginate content of the formulation significantly influenced the in vitro dissolution of the model drug (paracetamol). The drug release mechanism differed with the formulation variables, although if the pellets remained intact during the dissolution test, diffusion was the controlling mechanism. There was no significant advantage to be gained by using a mixture of the two polymers in terms of retarding drug release. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 60
页数:20
相关论文
共 21 条
[1]   SOME FACTORS INFLUENCING THE FORMATION AND IN-VITRO DRUG-RELEASE FROM MATRIX PELLETS PREPARED BY EXTRUSION SPHERONIZATION [J].
BLANQUE, D ;
STERNAGEL, H ;
PODCZECK, F ;
NEWTON, JM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 119 (02) :203-211
[2]   The influence of liquid binder on the liquid mobility and preparation of spherical granules by the process of extrusion/spheronization [J].
Boutell, S ;
Newton, JM ;
Bloor, JR ;
Hayes, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 238 (1-2) :61-76
[3]   Preparation of pellets of different shape and their characterization [J].
Chopra, R ;
Newton, JM ;
Alderborn, G ;
Podczeck, F .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2001, 6 (04) :495-503
[4]  
FIELDEN KE, 1988, J PHARM PHARMACOL, V40, P647
[5]   BINDER EFFECTIVENESS FOR BEADS WITH HIGH DRUG LEVELS [J].
FUNCK, JAB ;
SCHWARTZ, JB ;
REILLY, WJ ;
GHALI, ES .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (09) :1143-1156
[6]   MODIFIED DRUG RELEASE FROM BEADS PREPARED WITH COMBINATIONS OF 2 GRADES OF MICROCRYSTALLINE CELLULOSE [J].
GHALI, ES ;
KLINGER, GH ;
SCHWARTZ, JB .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1989, 15 (09) :1455-1473
[7]   AVICEL RC-591/CHITOSAN BEADS BY EXTRUSION-SPHERONIZATION TECHNOLOGY [J].
GOSKONDA, SR ;
UPADRASHTA, SM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1993, 19 (08) :915-927
[8]  
HARRISON PJ, 1985, J PHARM PHARMACOL, V37, P685
[9]   A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization [J].
Heng, PWS ;
Koo, OMY .
PHARMACEUTICAL RESEARCH, 2001, 18 (04) :480-487
[10]   Use of canonical and other analyses for the optimization of an extrusion-spheronization process for indomethacin [J].
Law, MFL ;
Deasy, PB .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 146 (01) :1-9